Category Medicines Licensing

Licensing routes to obtain a marketing authorisation for a medicine in the UK, GB or NI post Brexit

Last updated: 21 November 2024 To see updates, click on the ‘+’ sign below. Post Brexit, there are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotland and Wales) (GB) or Northern Ireland…

Read MoreLicensing routes to obtain a marketing authorisation for a medicine in the UK, GB or NI post Brexit

MHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025

The ILAP first launched in January 2021 to offer an integrated pre-market pathway awarding an Innovation Passport for promising medicines across England, Scotland and Wales. The pathway has seen an unprecedented number of applications and 160+ Innovation Passports have been…

Read MoreMHRA to relaunch the Innovative Licensing and Access Pathway (ILAP) pathway in Q1 2025

New MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

New guidance has been published on the MHRA website concerning process changes for the assessment of established medicines that come into effect on 1 March 2024. This post is an attempt to present the guidance information in a manner that…

Read MoreNew MHRA guidance on the assessment of established medicines in order to help applicants and shorten time frames

Swissmedic – changes to various guidance documents for the authorisation of human medicinal products

The table below details changes to five guidance documents (listed in column 1 below) for the authorisation of human medicinal products. Updated guidance document Document (plus form where applicable) What the document concerns Changes to the document Sections of the…

Read MoreSwissmedic – changes to various guidance documents for the authorisation of human medicinal products

MHRA announces new regulatory recognition routes for medicines licensing using approvals from various countries

The UK MHRA has announced today that new regulatory recognition routes for medicines will be established using approvals from the following countries: This means that patients will have access to safe and effective medicines that have been approved by trusted…

Read MoreMHRA announces new regulatory recognition routes for medicines licensing using approvals from various countries

Health Canada updates guidances concerning pre and post-licensing submissions and performance standards for Post-authorization Division 1 Changes (PDCs)

Health Canada has updated guidances concerning pre and post-licensing submissions and performance standards for PDCs for prescription pharmaceutical drugs and those administered or obtained through a health professional. Notice: Revision to the Guidance Document Management of Drug Submissions and Applications…

Read MoreHealth Canada updates guidances concerning pre and post-licensing submissions and performance standards for Post-authorization Division 1 Changes (PDCs)

Is the FDA allowing medicines authorised via the accelerated approval process to remain so in spite of unproven clinical effectiveness?

Is the FDA allowing medicines authorised via the accelerated approval process to remain so in spite of unproven clinical effectiveness? According to an investigation by the British Medical Journal (BMJ), 112 of the 253 drugs authorised by the FDA via…

Read MoreIs the FDA allowing medicines authorised via the accelerated approval process to remain so in spite of unproven clinical effectiveness?